ResMed Q1 EPS $2.92 as MatrixCare Sale Adds $62M Gain
RMD sits 40% above its 52-week low of $180.265.
Summary
ResMed reported Q1 revenue of $1.41B (+6%) and diluted EPS of $2.92, boosted by a $62M gain on the MatrixCare divestiture and a $855M quarter of share repurchases.
Key Events · Earnings and Guidance · RMD
-
Q1 Revenue Up 6% to $1.41B
Net revenue rose to $1,414.8M from $1,335.6M, with Sleep and Breathing Health up 8% to $1,259.8M and Residential Care Software down 7% to $155.0M.
-
EPS Boosted by Divestiture Gain
Diluted EPS was $2.92 versus $2.37; the $61.8M pre-tax gain on the MatrixCare sale contributed roughly $0.38 per share on a non-GAAP reconciliation basis.
-
MatrixCare Sale Closed September 1
Gross proceeds were $470M with $451M net of cash divested, a $62M pre-tax gain, and $10M of divestment-related costs.
-
Heavy Buyback Shrinks Share Count
ResMed repurchased 3.6M shares for $855M in the quarter, including a $450M ASR with an initial 1.6M shares delivered at a $230.87 reference price; 4.3M shares remain authorized.
Analysis · RMD · Industrial Applications And Services
ResMed's fiscal Q1 revenue rose 6% to $1.41B and diluted EPS jumped 23% to $2.92, but roughly $0.38 of that came from the $62M pre-tax gain on the MatrixCare sale, not operations. Core Sleep and Breathing Health revenue grew 8% while Residential Care Software fell 7% partly because MatrixCare is gone. The company also bought back 3.6M shares for $855M in the quarter, including a $450M accelerated repurchase, which shrinks the share count and flatters per-share figures. Operating income was essentially flat at $453M as R&D and SG&A both grew faster than revenue.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RMD was trading at $253.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $35.6B. The 52-week trading range was $180.27 to $277.67. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.